News Releases header image
 |
|
This section of the website contains information that should be considered accurate as of the date presented. You acknowledge that this information may change over time and you should not assume that the information is accurate at a later date. Quest Diagnostics is not obligated to update the information contained in this section of the website.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Test showed 100% specificity, with no false-positive results in the cohort, at both 3- and 5-year follow-up, and sensitivity of 100% and 83.3%, respectively, for predicting disease recurrence...
Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced today that it will report its third quarter 2026 financial results on Thursday, October 22, 2026,...
Study published in JAMA Network Open of over 193,000 patients nationwide reveals that individuals with evidence of exposure to Borrelia burgdorferi, the bacterium that causes Lyme disease, are...
75% of registered voters surveyed call diagnostic testing "very important" to their care, and a bipartisan majority wants Congress to pass the RESULTS Act before additional Medicare cuts are...
Coming later this year, Apple Health app users will be able to conveniently and securely purchase and receive results of Quest's biomarker lab testing directly in the app SECAUCUS, N.J., Sept. 9, 2026
Individuals in the U.S. can now add Humanity Biological Age’s lab-informed insights to select health profile tests purchased through Quest’s consumer-initiated testing platform LONDON, August...
Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that Jim Davis, Chairman, CEO and President, will speak on the company's strategy, performance...
Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that Sam Samad, Executive Vice President & Chief Financial Officer, will speak on the company's...
Test to join the company's expansive portfolio of Quest AD-Detect® blood tests for assessing symptomatic patients Quest also launching a new multi-biomarker AD-Detect® lab-developed blood test...
Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today announced that its Board of Directors declared a quarterly cash dividend of $0.86 per share, payable on October...
Largest nationally representative study finds 12% of patients positive for bacterial vaginosis are infected with at least one STI, such as chlamydia or gonorrhea SECAUCUS, N.J., July 30, 2026...
Second quarter revenues of $3.04 billion, up 10.2% from 2025, with 10.0% organic revenue growth Second quarter reported diluted earnings per share ("EPS") of $2.84, up 15.0% from 2025; and...
Hair test positivity among American workers reached 19.1% in 2025, potentially reflecting recurring or chronic drug use 15.1% of workers screened for drugs using a hair test were positive for...
American Oncology Network (AON) and other community oncology providers launching now as part of a pilot program that provides access to Haystack MRD SECAUCUS, N.J., July 8, 2026 /PRNewswire/ --...
Funding granted to four local organizations -- Florida International University Foundation, Urban Health Partnerships, The Health Council of South, and U.S. Hunger -- with goal to reach up to 15,000 residents over a 2-year period
Achieving the rigorous laboratory standard broadens access for providers and patients in New York; applies to use of Haystack MRD for patients with solid tumor cancers SECAUCUS, N.J., June 24,...
Published in Nature Communications, the new study finds that nearly 70% of a common bacterial strain that causes urinary tract infections, pneumonia and wound infections was non-susceptible to the...
Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced today that it will report its second quarter 2026 financial results on Thursday, July 23, 2026,...
Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today unveiled its 2025 Corporate Responsibility Report. The theme of the report, At the Center of Healthcare, reflects...
Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today announced that its Board of Directors declared a quarterly cash dividend of $0.86 per share, payable on July 22,...
Quest Diagnostics Incorporated (NYSE: DGX) (the "Company"), a leader in diagnostic information services, today announced the pricing of a public offering of $500 million aggregate principal amount...
First quarter revenues of $2.90 billion, up 9.2% from 2025, with 9.0% organic revenue growth First quarter reported diluted earnings per share ("EPS") of $2.24, up 15.5% from 2025; and adjusted...
Fourteen City of Hope sites across the U.S. participating in research using the Haystack MRD ctDNA Test in patients with breast, colorectal, ovarian, and prostate cancer SECAUCUS, N.J. and LOS ANGELES
Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced today that it will report first quarter 2026 financial results on Tuesday, April 21, 2026, before...
Quest Diagnostics Incorporated (NYSE: DGX), a leading provider of diagnostic information services, today announced that its board of directors has elected Timothy (Tim) Wentworth, a highly...
